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Sir,
In the comment of Dr Konstantopoulos ‘Gogas et al, give no
information pertaining to the status of melanoma cells circulating
in their patients before any surgical manipulation (i.e. at first
presentation). In our work (Gogas et al, 2002), in 27 patients
tested, one was already positive before operation becoming
negative some time following operation’ we would like to state
that more than 95% of the patients referred to our Center have
already been diagnosed with melanoma and require wide local
excision, sentinel lymph node and consideration for adjuvant
treatment. So, it was not possible to obtain blood from patients
before any surgical manipulation. Perhaps, they should define if
this was the case in the 27 patients they studied in the work they
have published.
Concerning the comment ‘This type of information may permit
further confirmation of a theory claiming that surgery manipula-
tions may cause forced release of melanocytes to blood circulation’
in our discussion, we argue that even though this is not a
randomised study and there were no untreated patients, and one
could speculate that the conversion was a consequence of greater
time after surgery, the surgery in this case either dislodging
tumour cells or removing the source of tumour cells, the lower
probability of recurrence strongly argues that the reversion was a
consequence of interferon therapy.
Finally, I cannot reconcile why Dr Konstantopoulos believes that
‘for a more reliable conclusion to be drawn, as interferon
administration could possibly induce transcription of tyrosinase
gene, one should also include subjects under similar doses of
interferon for other purposes as controls’. The regiment used in
our study is only approved by the FDA for high-risk melanoma
patients.
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